Nishkruti Bio-Pharma Profile
Key Indicators
- Authorised Capital ₹ 430.00 Cr
as on 08-07-2024
- Paid Up Capital ₹ 334.15 Cr
as on 08-07-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2021)
- Profit 29.53%
(FY 2021)
- Ebitda -836.92%
(FY 2021)
- Net Worth 110.21%
(FY 2021)
- Total Assets 31.91%
(FY 2021)
About Nishkruti Bio-Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 430.00 Cr and a paid-up capital of Rs 334.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Nishkruti Bio-Pharma Private Limited India is Amit Joshi as COMPANY SECRETARY. Hrishikesh Ponkshe and Dattatraya Dhavalikar serve as directors at the Company.
- CIN/LLPIN
U24304TN2017PTC120869
- Company No.
120869
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2017
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nishkruti Bio-Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Joshi  | Company Secretary | 01-Apr-2019 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hrishikesh Ponkshe | Director | 31-Jul-2017 | Current |
| Dattatraya Dhavalikar | Director | 16-Apr-2019 | Current |
Financial Performance and Corporate Structure Insights of Nishkruti Bio-Pharma.
Nishkruti Bio-Pharma Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 29.53% increase in profit. The company's net worth Soared by an impressive increase of 110.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nishkruti Bio-Pharma?
In 2021, Nishkruti Bio-Pharma had a public holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Serum Institute Vaccines Private LimitedActive 3 years 7 monthsHrishikesh Ponkshe is a mutual person
Vakzine Pharma Private LimitedActive 7 years 4 monthsHrishikesh Ponkshe and Dattatraya Dhavalikar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nishkruti Bio-Pharma?
Unlock and access historical data on people associated with Nishkruti Bio-Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nishkruti Bio-Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nishkruti Bio-Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
